These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7091448)

  • 1. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
    van Kammen DP; Bunney WE; Docherty JP; Marder SR; Ebert MH; Rosenblatt JE; Rayner JN
    Am J Psychiatry; 1982 Aug; 139(8):991-7. PubMed ID: 7091448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextro-amphetamine diminishes negative symptoms in schizophrenia.
    van Kammen DP; Boronow JJ
    Int Clin Psychopharmacol; 1988 Apr; 3(2):111-21. PubMed ID: 3294284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
    Goldberg TE; Bigelow LB; Weinberger DR; Daniel DG; Kleinman JE
    Am J Psychiatry; 1991 Jan; 148(1):78-84. PubMed ID: 1984711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine and lithium response in the schizophrenias.
    Edelstein P; Schultz JR; Hirschowitz J; Kanter DR; Garver DL
    Am J Psychiatry; 1981 Aug; 138(8):1078-81. PubMed ID: 7258385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Dalton L; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):261-6. PubMed ID: 7065839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
    van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia.
    Pandurangi AK; Goldberg SC; Brink DD; Hill MH; Gulati AN; Hamer RM
    Biol Psychiatry; 1989 Jan; 25(2):207-14. PubMed ID: 2649157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
    Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
    van Kammen DP; Docherty JP; Bunney WE
    Biol Psychiatry; 1982 Feb; 17(2):233-42. PubMed ID: 7074181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.
    Wolkin A; Sanfilipo M; Angrist B; Duncan E; Wieland S; Wolf AP; Brodie JD; Cooper TB; Laska E; Rotrosen JP
    Biol Psychiatry; 1994 Sep; 36(5):317-25. PubMed ID: 7993958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-dose, double-blind study of ceruletide in the treatment of schizophrenia.
    Mattes JA; Hom W; Rochford JM
    Am J Psychiatry; 1985 Dec; 142(12):1482-4. PubMed ID: 3907376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of schizophrenia with a vasopressin analogue.
    Iager AC; Kirch DG; Bigelow LB; Karson CN
    Am J Psychiatry; 1986 Mar; 143(3):375-7. PubMed ID: 3513631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.